Radiation Oncology

Table 4 Multivariate analysis as a function of radiated site

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

		Extracranial Radiation (n = 13,586)			Intracranial Radiation (n = 8624)
		Hazard Ratio	95% Confidence Interval	p-value	Hazard Ratio	95% Confidence Interval	p-value
Sex	Male	1.00	Ref	< 0.0001	1.00	Ref	< 0.0001
Sex	Female	0.85	0.81–0.89	< 0.0001	0.82	0.78–0.86	< 0.0001
Age	18–59	1.00	Ref	0.087	1.00	Ref	< 0.0001
	60–69	0.98	0.94–1.03		1.10	1.04–1.16
	70–79	1.00	0.95–1.05		1.27	1.19–1.35
	80+	1.10	1.01–1.20		1.43	1.24–1.64
Comorbidity	0	1.00	Ref	0.002	1.00	Ref	< 0.0001
	1	1.04	0.99–1.08		1.09	1.03–1.15
	> 2	1.12	1.05–1.20		1.25	1.15–1.36
Histology	Adenocarcinoma	1.00	Ref	< 0.0001	1.00	Ref	< 0.0001
Histology	Non-adenocarcinoma	1.09	1.05–1.14	< 0.0001	1.18	1.13–1.25	< 0.0001
Race	White	1.00	Ref	< 0.0001	1.00	Ref	< 0.0001
Race	Non-white	0.88	0.83–0.92	< 0.0001	0.86	0.80–0.92	< 0.0001
Insurance	Uninsured	1.00	Ref	0.753	1.00	Ref	0.533
Insurance	Insured	1.02	0.92–1.12	0.753	1.04	0.93–1.16	0.533
Facility Type	Academic	1.00	Ref	< 0.0001	1.00	Ref	< 0.0001
Facility Type	Nonacademic	1.11	1.07–1.16	< 0.0001	1.21	1.15–1.27	< 0.0001
Systemic Therapy	Chemotherapy	1.00	Ref	0.002	1.00	Ref	< 0.0001
Systemic Therapy	Immunotherapy	0.90	0.85–0.96	0.002	0.83	0.77–0.90	< 0.0001
Radiation	EBRT	1.00	Ref	< 0.0001	1.00	Ref	< 0.0001
Radiation	SRT	0.51	0.45–0.58	< 0.0001	0.62	0.58–0.66	< 0.0001

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com